{"paper_id":"ca9fb069-0393-4866-ae71-1a5844bfba04","body_text":"Abstract\nMifepristone, a progesterone receptor antagonist, was initially used to terminate early pregnancy. As scientific research advanced, it emerged to be effective in the treatment of various tumors and tumor-like conditions such as endometriosis. Despite the therapeutic potential of mifepristone, its therapeutic effect is still far from ideal because the drug is difficult to dissolve and to accumulate in the target tissue sites. To address this issue, mifepristone-loaded nanostructured lipid carriers (Mif-NLC) were prepared by a simple solvent diffusion method and their anti-endometriosis performance and mechanisms were initially investigated. By optimizing the preparation protocol, we obtained uniform and spheroidal Mif-NLC with an average particle size of 280 nm. The encapsulation rate and drug loading capacity were 64.67% ± 0.15% and 2.7% ± 0.014%, respectively, as measured by UV spectrophotometry. The in vitro release kinetics indicated that mifepristone was released from NLC in a sustained-release manner. Compared with free mifepristone, Mif-NLC exhibited enhanced cellular uptake and inhibition of invasion activity in primary mesenchymal cells of endometriosis. A certain reduction in the size of endometriotic cysts was observed in animals compared to controls. The induction of autophagy via Mif-NLC may serve as the molecular mechanism underlying this effect. Furthermore, observation of uterine structures showed negligible toxic effects. This suggested that mifepristone encapsulated in NLC can improve its bioavailability and anti-endometriosis efficacy, which provided a new strategy for the treatment of endometriosis.\nGraphical Abstract\nSimilar content being viewed by others\nData availability\nThe collected and analyzed datasets during the current study are available from the corresponding author on reasonable request.\nReferences\nBurney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertility Steril Oct. 2019;112(4):E153–61. https://doi.org/10.1016/j.fertnstert.2019.08.083\nWang HX, Ni CX, Xiao W, Wang SL. Role of lncRNA FTX in invasion, metastasis, and epithelial-mesenchymal transition of endometrial stromal cells caused by endometriosis by regulating the PI3K/Akt signaling pathway. Annals Translational Med Nov. 2020;8(22):1504. https://doi.org/10.21037/atm-20-6810\nKoninckx PR, Ussia A, Adamyan L, Wattiez A, Donnez J. Deep endometriosis: definition, diagnosis, and treatment. Fertility Steril Sep. 2012;98(3):564–71. https://doi.org/10.1016/j.fertnstert.2012.07.1061\nUzuner C, Mak J, El-Assaad F, Condous G. The bidirectional relationship between endometriosis and microbiome. Front Endocrinol Mar. 2023;141110824. https://doi.org/10.3389/fendo.2023.1110824\nGu YR, Ding ZY, Zhou Q, Li J, Qian WY. JARID2 regulates epithelial mesenchymal transition through the PTEN/ AKT signalling pathways in ovarian endometriosis. Reproductive Biology Mar. 2023;23(1):100729. https://doi.org/10.1016/j.repbio.2023.100729\nMei J, Zhu XY, Jin LP, Duan ZL, Li DJ, Li MQ. Estrogen promotes the survival of human secretory phase endometrial stromal cells via CXCL12/CXCR4 up-regulation-mediated autophagy inhibition. Hum Reprod Jul. 2015;30(7):1677–89. https://doi.org/10.1093/humrep/dev100\nMoses AS, Taratula OR, Lee H, et al. Nanoparticle-based platform for Activatable Fluorescence Imaging and photothermal ablation of endometriosis. Small May. 2020;16(18):1906936. https://doi.org/10.1002/smll.201906936\nde Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet Aug-Sep. 2010;376(9742):730–8. https://doi.org/10.1016/s0140-6736(10)60490-4\nHe WL, Horn SW, Hussain MD. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm Apr. 2007;334(1–2):173–8. https://doi.org/10.1016/j.ijpharm.2006.10.025\nLlaguno-Munive M, Medina LA, Jurado R, Romero-Pina M, Garcia-Lopez P. Mifepristone improves chemo-radiation response in glioblastoma xenografts. Cancer Cell Int Mar. 2013;1329. https://doi.org/10.1186/1475-2867-13-29\nZheng N, Chen JH, Liu WQ, et al. Mifepristone inhibits ovarian cancer metastasis by intervening in SDF-1/CXCR4 chemokine axis. Oncotarget Aug. 2017;8(35):59123–35. https://doi.org/10.18632/oncotarget.19289\nJiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xu HM. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertility Steril May. 2002;77(5):995–1000. https://doi.org/10.1016/s0015-0282(02)03081-9. Pii s0015-0282(02)03081-9.\nKettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SSC. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertility Steril Jan. 1996;65(1):23–8.\nXue HL, Yu N, Wang J, Hao WJ, Li Y, Liu MY. Therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis. Pakistan J Med Sci Sep-Oct. 2016;32(5):1268–72. https://doi.org/10.12669/pjms.325.10772\nChe X, Wang JZ, He JY, et al. A new trick for an old dog: the application of mifepristone in the treatment of adenomyosis. J Cell Mol Med Jan. 2020;24(2):1724–37. https://doi.org/10.1111/jcmm.14866\nFedele L, Berlanda N. Emerging drugs for endometriosis. Expert opinion on emerging drugs. 2004 2004;9(1):167– 77. https://doi.org/10.1517/14728214.9.1.167\nSarkar NN. Mar. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2002;101(2):113–20. Pii s0301-2115(01)00522-x. https://doi.org/10.1016/s0301-2115(01)00522-x\nMei L, Bao JB, Tang LN, et al. A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies. Eur J Pharm Sci Mar. 2010;39(5):421–7. https://doi.org/10.1016/j.ejps.2010.01.012\nMuller RH, Radtke M, Wissing SA. Nov. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug Delivery Reviews. 2002;54:S131-S155. Pii s0169-409x(02)00118-7. https://doi.org/10.1016/s0169-409x(02)00118-7\nSalvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Delivery Sci Technol Jun. 2019;51:255–67. https://doi.org/10.1016/j.jddst.2019.02.017\nDhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem Apr. 2021;9580118. https://doi.org/10.3389/fchem.2021.580118\nMiao J, Du YZ, Yuan H, et al. Improved cytotoxicity of paclitaxel loaded in nanosized lipid carriers by intracellular delivery. J Nanoparticle Res Jan. 2015;17(1):10. https://doi.org/10.1007/s11051-014-2852-x\nZhang HJ, Wu FQ, Li YZ, et al. Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone. Beilstein J Nanatechnol Nov. 2016;7:1861–70. https://doi.org/10.3762/bjnano.7.178\nEtheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine-Nanotechnology Biology Med Jan. 2013;9(1):1–14. https://doi.org/10.1016/j.nano.2012.05.013\nTang M, Xin Y, Zhao YC, et al. Placenta-anchored tadalafil liposomes rescues intrauterine growth restriction through continuous placental blood perfusion improvement. J Controlled Release Apr. 2024;368:466–80. https://doi.org/10.1016/j.jconrel.2024.03.004\nMuller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Delivery Reviews Mar. 2001;47(1):3–19. https://doi.org/10.1016/s0169-409x(00)00118-6\nZhan L, Li J, Wei B. Jan. Autophagy in endometriosis: friend or foe? Biochemical and Biophysical Research Communications. 2018;495(1):60–3. https://doi.org/10.1016/j.bbrc.2017.10.145\nTenchov R, Bird R, Curtze AE, Zhou QQ. Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a Landscape of Research Diversity and Advancement. Acs Nano Nov. 2021;15(11):16982–7015. https://doi.org/10.1021/acsnano.1c04996\nManzanares D, Cena V, Endocytosis. The nanoparticle and submicron nanocompounds gateway into the cell. Pharm Apr. 2020;12(4):371. https://doi.org/10.3390/pharmaceutics12040371\nNeves AR, Queiroz JF, Lima SAC, Figueiredo F, Fernandes R, Reis S. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: relevance for oral drug delivery. J Colloid Interface Sci Feb. 2016;463:258–65. https://doi.org/10.1016/j.jcis.2015.10.057\nJeitler R, Glader C, Tetyczka C, et al. Investigation of Cellular interactions of lipid-structured nanoparticles with oral mucosal epithelial cells. Front Mol Biosci May. 2022;9917921. https://doi.org/10.3389/fmolb.2022.917921\nJain AK, Thareja S. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. Artif Cells Nanomed Biotechnol. 2019;47(1):524–39. https://doi.org/10.1080/21691401.2018.1561457\nMartins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm Jul. 2012;430(1–2):216–27. https://doi.org/10.1016/j.ijpharm.2012.03.032\nGao Y, Gu SG, Zhang YY, et al. The architecture and function of monoclonal antibody-functionalized mesoporous silica nanoparticles loaded with mifepristone: repurposing abortifacient for cancer metastatic chemoprevention. Small May. 2016;12(19):2595–608. https://doi.org/10.1002/smll.201600550\nSchneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). Journal of the Society for Gynecologic Investigation. Nov-Dec. 1998;5(6):334–8. https://doi.org/10.1016/s1071-5576(98)00037-9\nCheck JH, Check D, Poretta T, Wilson C. Palliative benefits of oral mifepristone for the treatment of metastatic fibroblastic osteosarcoma. Anticancer Res Apr. 2021;41(4):2111–5. https://doi.org/10.21873/anticanres.14982\nGamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. Bmc Cancer May. 2012;12200. https://doi.org/10.1186/1471-2407-12-200\nSchreinemacher MH, Backes WH, Slenter JM, et al. Towards endometriosis diagnosis by Gadofosveset-Trisodium enhanced magnetic resonance imaging. Plos One Mar. 2012;7(3):e33241. https://doi.org/10.1371/journal.pone.0033241\nGuo XM, Li W, Zhou JL, et al. Specific photothermal ablation therapy of endometriosis by targeting delivery of gold nanospheres. Small Apr. 2017;13(15):1603270. https://doi.org/10.1002/smll.201603270\nJerman LF, Hey-Cunningham AJ. The role of the lymphatic system in endometriosis: a comprehensive review of the literature. Biology Reprod Mar. 2015;92(3):64. https://doi.org/10.1095/biolreprod.114.124313\nShen HH, Zhang T, Yang HL, et al. Ovarian hormones-autophagy-immunity axis in menstruation and endometriosis. Theranostics. 2021;11(7):3512–26. https://doi.org/10.7150/thno.55241\nZhao MD, Zhang M, Yu Q, et al. Hyaluronic acid-modified nanoplatforms as a Vector for targeted delivery of autophagy-related gene to the endometriotic lesions in mice. Front Bioeng Biotechnol Jul. 2022;10918368. https://doi.org/10.3389/fbioe.2022.918368\nAllavena G, Carrarelli P, Del Bello B, Luisi S, Petraglia F, Maellaro E. May. Autophagy is upregulated in ovarian endometriosis: a possible interplay with p53 and heme oxygenase-1. Fertility and sterility. 2015;103(5):1244–. https://doi.org/10.1016/j.fertnstert.2015.02.007\nZhang L, Hapon MB, Goyeneche AA, et al. Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Mol Oncol Aug. 2016;10(7):1099–117. https://doi.org/10.1016/j.molonc.2016.05.001\nFu J, Song H, Zhou M, et al. Progesterone receptor modulators for endometriosis. Cochrane Database Syst Reviews. 2017. https://doi.org/10.1002/14651858.CD009881.pub2. (7)Cd0098811.\nAcknowledgements\nWe are thankful for the funding from the National Natural Science Foundation of China (82071616 and 82103505) and the Nature Science Foundation of Zhejiang province (LY19H040011 and LQ22H040005).\nAuthor information\nAuthors and Affiliations\nContributions\nAll authors contributed to the manuscript. Conceptualization: Jingjing Yan and Mengdan Zhao. Formal analysis and investigation: Yujie Peng and Shiyao Huang. Methodology and data curation: Jingjing Yan, Yujie Peng, Shiyao Huang, and Meng Zhang. Funding acquisition: Mengdan Zhao, and Meng Zhang. Writing—original draft: Jingjing Yan. Writing—review and editing: Yue Chen and Weidong Fei. Supervision: Caihong Zheng, Meng Zhang and Mengdan Zhao.\nCorresponding authors\nEthics declarations\nEthics approval and consent to participate\nThe animal experiment was conducted in line with the ethical guidelines set forth by the Experimental Animal Ethics Committee of Zhejiang University and the approval no. for animal protocol is ZJCLA-IACUC-20010072.\nConsent for publication\nThe authors declare that they have provided their consent for publishing this manuscript.\nCompeting interests\nThe authors report no conflicts of interest in this work.\nAdditional information\nPublisher’s Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nElectronic supplementary material\nBelow is the link to the electronic supplementary material.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nYan, J., Peng, Y., Huang, S. et al. Treatment of endometriosis with mifepristone mediated by nanostructured lipid carriers. Drug Deliv. and Transl. Res. 15, 1181–1192 (2025). https://doi.org/10.1007/s13346-024-01661-3\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s13346-024-01661-3","source_license":"CC0","license_restricted":false}